Amylin (AMLN) Tumbles as Competitor to Byetta, Novo Nordisk's liraglutide, Does Not Receive FDA Recommendation

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/21/2026

1. TGT
2. WMT
3. SPY
4. ROST
5. EL
6. ADI
7. LOW
8. MRK
9. BILL
10. NTES

Go back to Amylin (AMLN) Tumbles as Competitor to Byetta, Novo Nordisk's liraglutide, Does Not Receive FDA Recommendation
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) Delayed: 30.98 --0 (-0%)
Previous Close $30.98    52 Week High $31.02 
Open $3.30    52 Week Low $8.03 
Day High $30.98    P/E N/A 
Day Low $30.98    EPS $-4.38 
Volume 440,704       

ASTRAZENECA PLC (NASDAQ: AZN) Delayed: 92.77 --0 (-0%)
Previous Close $92.77    52 Week High $35.04 
Open $92.77    52 Week Low $26.97 
Day High $92.77    P/E N/A 
Day Low $92.77    EPS $0.00 
Volume 7,360       

Bristol-Myers Squibb (NYSE: BMY) Delayed: 65.47 --0 (-0%)
Previous Close $65.47    52 Week High $77.12 
Open $65.47    52 Week Low $49.03 
Day High $65.47    P/E 42.51 
Day Low $65.47    EPS $1.54 
Volume 398       

NOVO-NORDISK A/S (NYSE: NVO) Delayed: 46.14 --0 (-0%)
Previous Close $46.14    52 Week High $59.00 
Open $46.14    52 Week Low $32.80 
Day High $46.14    P/E N/A 
Day Low $46.14    EPS $0.00 
Volume 146,769